An earlier version of this report said 23andMe would start trading Tuesday on the New York Stock Exchange. It will start trading on Thursday on Nasdaq. The article has been corrected.
The company is aiming to offer 25 million shares priced at $16 to $18 each to raise up to $450 million to fund its clinical trials and research and development efforts at a valuation of almost $5 billion. Lyell has applied to list on Nasdaq, under the ticker “LYEL.” Goldman Sachs, BofA Securities, JP Morgan and Morgan Stanley are underwriting the deal.
See now: Rich IPO paydays for Airbnb, DoorDash CEOs lead influential advisory firms to target execs at their first shareholder meetings AiHuiShou International, which began life as a smartphone recycling business, operates the PJT Marketplace and the Paipai Marketplace with a mission of giving “a second life to all idle goods.” The company has 755 online stores in 172 cities, according to its IPO documents.
Next on the list is German psychedelics startup ATAI Life Sciences ATAI, , which is aiming to develop new treatments for mental health disorders. The company has applied to list on Nasdaq, under the ticker symbol “IPSC.” JP Morgan, BofA Securities, SVB Leerink and Piper Sandler are underwriting the deal. Proceeds will be used to fund pre-clinical activity and research and development, as well as working capital and general corporate purposes.
23andme is included on this list.. that’s interesting 🤔😊
Trippy